MAPT and Alzheimer disease: Lyu, D. et al[43] designed systematic review and network meta-analysis protocols focusing on the cognitive benefits of various drug categories, such as anti-beta-amyloid, anti-Tau, metabolism, symptomatic, etc. These protocols have the potential to uncover key factors in treating AD and preserving cognitive function.